BETHESDA, Md., Dec. 4, 2017 /PRNewswire/ — Northwest Biotherapeutics (OTCQB: NWBO) (NWBio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it has completed a $12 million financing to fund operations. The majority of the…
